Trial Profile
A phase II trial of docetaxel/prednisone in combination with sargramostim as treatment for hormone-refractory prostate cancer.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Docetaxel (Primary) ; Prednisone (Primary) ; Sargramostim (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 01 Dec 2010 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
- 20 Aug 2008 Planned end date (Dec 2008) added as reported by ClinicalTrials.gov.
- 08 May 2008 Status changed from recruiting to in porgress.